Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
The present invention relates to pure crystalline Form II of an L-malic acid salt of sunitinib and a process for its preparation. The invention further provides crystalline Form II of an L-malic acid salt of sunitinib having a purity of at least 97.0%. The invention also provides crystalline Form II of an L-malic acid salt of sunitinib substantially free of an anti-oxidant. The invention also provides crystalline Form II of L-malic acid salt of sunitinib which remains chemically pure on storage at 25° C.±2° C. and 40° C.±2° C. at a relative humidity of 60%±5% and 75%±5%, respectively, for at least 1 month.
1. A pure crystalline Form II of an L-malic acid salt of sunitinib characterized by the data selected from the group consisting of:
an X-Ray Powder Diffraction (XRPD) pattern substantially as depicted in FIG. 1 , and a purity of at least 97.0%,
and is chemically stable and does not degrade on storage at 25° C.±2° C. and 40° C.±2° C. at a relative humidity of 60%±5% and 75%±5%, respectively, for at least 1 month, where the pure crystalline Form II of an L-malic acid salt of sunitinib is prepared by adding an anti-oxidant to a mixture of L-malic acid and sunitinib.
2. A process for the preparation of pure crystalline Form II of an L-malic acid salt of sunitinib wherein the process comprises:
a) adding an anti-oxidant to a mixture of L-malic acid and sunitinib; and
b) isolating pure crystalline Form II of the L-malic acid salt of sunitinib from the mixture obtained in step a).
3. The process according to claim 2 , wherein the anti-oxidant used is organic or inorganic.
4. The process according to claim 3 , wherein the organic anti-oxidant used is selected from the group consisting of ascorbic acid, L-ascorbic acid, sodium ascorbate, calcium ascorbate, fatty acid esters of ascorbic acid, vitamins A and E, lipoic acid, uric acid, carotenes, glutathione, melatonin, tocopheroles, propylgallate (PG), octylgallate, dodecylgallate, tertiary butylhydroquinone (TBHQ), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), erythorbic acid, sodium erythorbate, 4-hexylresorcinol, polyphenols, and mixtures thereof.
5. The process according to claim 3 , wherein the inorganic anti-oxidant is sodium metabisulfite.
6. The process according to claim 2 , wherein the addition of the anti-oxidant to a mixture of L-malic acid and sunitinib is carried out in the presence of a solvent selected from the group consisting of water, ethers, alcohols, ketones, hydrocarbons, esters, halogenated hydrocarbons, and mixtures thereof.
7. The process according to claim 2 , wherein the pure crystalline Form II of the L-malic acid salt of sunitinib is obtained from the reaction mixture by spray drying, freeze drying, agitated thin film drying, melt extrusion, solvent evaporation, desolvation, ball milling, or precipitation.
8. The process according to claim 6 , wherein the addition of the anti-oxidant to a mixture of L-malic acid and sunitinib is carried out in water.
9. A process for the preparation of pure crystalline Form II of an L-malic acid salt of sunitinib, wherein the process comprises:
a) adding sunitinib ascorbate to a mixture of L-malic acid and sunitinib; and
b) isolating pure crystalline Form II of the L-malic acid salt of sunitinib from the reaction mixture obtained in step a).
10. A process for the preparation of pure crystalline Form II of L-malic acid salt of sunitinib, wherein the process comprises:
a) reacting sunitinib ascorbate with L-malic acid; and
b) isolating pure crystalline Form II of the L-malic acid salt of sunitinib from the reaction mixture thereof.
11. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 1 substantially free of an anti-oxidant.
12. The pure crystalline Form II of the L-malic acid salt of sunitinib according to claim 11 , which has an anti-oxidant content of less than 2.0%.
13. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 1 substantially free of ascorbic acid.
14. The pure crystalline Form II of the L-malic acid salt of sunitinib according to claim 13 , which has an ascorbic acid content of less than 2.0%.
15. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 1 , wherein the anti-oxidant is organic or inorganic.
16. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 15 , wherein the organic anti-oxidant is selected from the group consisting of ascorbic acid, L-ascorbic acid, sodium ascorbate, calcium ascorbate, fatty acid esters of ascorbic acid, vitamins A and E, lipoic acid, uric acid, carotenes, glutathione, melatonin, tocopheroles, propylgallate (PG), octylgallate, dodecylgallate, tertiary butylhydroquinone (TBHQ), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), erythorbic acid, sodium erythorbate, 4-hexylresorcinol, polyphenols, and mixtures thereof.
17. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 15 , wherein the inorganic anti-oxidant is sodium metabisulfite.
18. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 1 , wherein the step of adding the anti-oxidant to a mixture of L-malic acid and sunitinib is carried out in the presence of a solvent selected from the group consisting of water, ethers, alcohols, ketones, hydrocarbons, esters, halogenated hydrocarbons, and mixtured thereof.
19. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 18 , wherein the step of adding the anti-oxidant to a mixture of L-malic acid and sunitinib is carried out in water.
20. The pure crystalline Form II of an L-malic acid salt of sunitinib according to claim 1 , wherein the pure crystalline Form II of the L-malic acid salt of sunitinib is obtained by spray drying, freeze drying, agitated thin film drying, melt extrusion, solvent evaporation, desolvation, ball milling, or precipitation.